Formulary
Pneumococcal polysaccharide conjugate vaccine (adsorbed): Indications, Dosing, Side Effects and Interactions
For pneumococcal polysaccharide conjugate vaccine (adsorbed) In adults: Pneumococcal polysaccharide conjugate vaccine is an inactivated vaccine that protects...
MedNext Academy | 3 min read
Pneumococcal polysaccharide conjugate vaccine (adsorbed): Indications, Dosing, Side Effects and Interactions
For pneumococcal polysaccharide conjugate vaccine (adsorbed) In adults: Pneumococcal polysaccharide conjugate vaccine is an inactivated vaccine that protects...
Drug action
For pneumococcal polysaccharide conjugate vaccine (adsorbed) In adults: Pneumococcal polysaccharide conjugate vaccine is an inactivated vaccine that protects against infection caused by Streptococcus pneumoniae . The conjugate vaccine contains adsorbed pneumococcal polysaccharide from either 13 capsular types (13-valent Prevenar 13 ), 15 capsular types (15-valent Vaxneuvance ), or 20 capsular types (20-valent Prevenar 20 ). For information on the non-conjugate vaccine, see pneumococcal polysaccharide vaccine . In children: Pneumococcal polysaccharide conjugate vaccine is an inactivated vaccine that protects against infection caused by Streptococcus pneumoniae . The conjugate vaccine contains adsorbed pneumococcal polysaccharide from either 13 capsular types (13-valent Prevenar 13 ), 15 capsular types (15-valent Vaxneuvance ), or 20 capsular types (20-valent Prevenar 20 ).
Indications and dose
**Primary immunisation against pneumococcal infection**
- **Child** (By Intramuscular Injection): 16 weeks 0.5 mL for 1 dose.
- **Elderly** (By Intramuscular Injection): 0.5 mL for 1 dose.
**Immunisation against pneumococcal infection [booster dose]**
- **Child** (By Intramuscular Injection): 1 year 0.5 mL for 1 dose.
**Immunisation against pneumococcal infection [in patients with unknown or incomplete immunisation status]**
- **Child** (By Intramuscular Injection): 12-23 months 0.5 mL for 1 dose.
**Primary immunisation against pneumococcal infection for pneumococcal polysaccharide conjugate vaccine (adsorbed)**
- **Child 16 weeks** (By intramuscular injection): 0.5 mL for 1 dose.
**Immunisation against pneumococcal infection [booster dose] for pneumococcal polysaccharide conjugate vaccine (adsorbed)**
- **Child 1 year** (By intramuscular injection): 0.5 mL for 1 dose.
**Immunisation against pneumococcal infection [in patients with unknown or incomplete immunisation status] for pneumococcal polysaccharide conjugate vaccine (adsorbed)**
- **Child 4-11 months** (By intramuscular injection): 0.5 mL for 1 dose, followed by 0.5 mL for 1 dose, to be given on or after their first birthday at least 4 weeks after the first dose.
- **Child 12-23 months** (By intramuscular injection): 0.5 mL for 1 dose.
Cautions
For all vaccines, general Acute illness; minor illnesses Cautions, further information Illness UKHSA advises vaccination may be postponed if the individual is suffering from an acute illness; however, it is not necessary to postpone immunisation in patients with minor illnesses without fever or systemic upset. Predisposition to neurological problems UKHSA advises: when there is a personal or family history of febrile convulsions, there is an increased risk of these occurring during fever from any cause including immunisation, but this is not a contra-indication to immunisation. In children who have had a seizure associated with fever without neurological deterioration, immunisation is recommended ; advice on the management of fever should be given before immunisation. When a child has had a convulsion not associated with fever, and the neurological condition is not deteriorating, immunisation is recommended ; children with stable neurological disorders (e.g. spina bifida, congenital brain abnormality, and peri-natal hypoxic-ischaemic encephalopathy) should be immunised according to the recommended schedule; when there is a still evolving neurological problem , including poorly controlled epilepsy, immunisation should be deferred and the child referred to a specialist. Immunisation is recommended if a cause for the neurological disorder is identified. If a cause is not identified, immunisation should be deferred until the condition is stable. Impaired immune response and drugs affecting immune response Immune response to vaccines may be reduced in immunosuppressed patients, UKHSA advises consider seeking specialist advice.
Side effects
For all vaccines, general Common or very common Abdominal pain; appetite decreased; arthralgia; diarrhoea; dizziness; fatigue; fever; headache; lymphadenopathy; malaise; myalgia; nausea; skin reactions; vomiting Uncommon Hypersensitivity Side-effects For pneumococcal polysaccharide conjugate vaccine (adsorbed) Common or very common Drowsiness (in children); irritability (in children); sleep disorder (in children) Uncommon Crying (in children); seizures (in children) Rare or very rare Hypotonic-hyporesponsiveness episode (in children)
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Pneumococcal polysaccharide conjugate vaccine (adsorbed) in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

